Phase III Randomized Study Of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy And Consolidation Therapy In Actively Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia Read more
Phase III Randomized Trial Of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery Or Radiation) Of The Primary Tumor In Metastatic Prostate Cancer Read more
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With Or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer Read more
Intuitive Surgical, Protocol: ISI-IRIS-002 , PI: Dr. Stifelman, Title: A Prospective Post-Market Study To Evaluate The Clinical Utility Of IRISTM, A Three-Dimensional (3-D) Anatomical Modeling Software For Pre-Operative Surgical Planning And Intra-Operative Navigation For Nephrectomy Read more
Phase II Trial Of Intravesical Gemcitabine And MK-3475 (Pembrolizumab) In The Treatment Of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Read more
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study To Compare Tivozanib In Combination With Nivolumab To Tivozanib In Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines Of Therapy, One Of Which Is An Immune Checkpoint Inhibitor Read more
A Phase II/III Trial Of MEDI4736 (Durvalumab) And Chemotherapy For Patients With High Grade Upper Tract Urothelial Cancer Prior To Nephroureterectomy Read more
A Phase I/II Study Evaluating The Dosing, Safety, Efficacy, And Biological Activity Of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Neoadjuvant Chemotherapy (NACT) In Patients Actively Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer Read more
A Phase Ib Safety Run-In And Randomized Phase II, Open-Label Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of M6620 In Combination With Avelumab And Carboplatin In Comparison To Standard Of Care Therapy In Participants With Parpi-Resistant Recurrent Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Read more
